[EXTRACORPOREAL BLOOD CORRECTION METHODS AND THEIR IMPACT ON PRODUCTS OF MICROBIAL METABOLISM IN PATIENTS WITH SEPSIS].

Sepsis is a disease with a high death-rate and is accompanied by profound metabolic disturbances. Interference of microbe metabolic products with biochemical processes in human organism is present in case of severe infection. But there is little information about integration of microbe and human metabolism in septic patients.

[Elimination of inflammatory mediators in sepsis by means of sorption detoxification methods].

The levels of pro- and anti-inflammatory cytokines were studied in 31 patients with sepsis of varying etiology; in 17 patients of them hemosorption through the antiproteinase sorbent Ovosorb was included into a complex of traditional intensive care, in 14 patients hemocarboperfusion was made through the carbon hemosorbent Simplex-F. The sorption detoxification methods were found to cause a reduction in the excessive levels of blood inflammatory cytokines, the hemosorbent Ovosorb showing the most pronounced eliminating effect. At the same time, there was an increase in the blood level of anti-inflammatory mediators in patients on Ovosorb hemosorption.

[Effect of extracorporeal autohemomagnetic therapy on oxygen balance in patients with acute lung injury syndrome in sepsis].

The paper shows the results of a study evaluating the impact of impulse magnetic fields on the blood of patients with acute lung injury concurrent with sepsis. Extracorporeal autohemomagnetic therapy has been ascertained to reduce blood and tissue hypoxia. Thus it normalizes basic oxygen homeostasis more effectively than do traditional methods.

[Clinical course and intensive therapy of sepsis in geriatric patients].

A comparative analysis was performed of a clinical course and intensive therapy of sepsis in 43 patients over 60 years of age. 86% of them were patients aged 60 to 74 years, the rest were older. The intensive therapy included: surgical treatment of the infection focus (on demand), antibiotics, immunomodulators (immunoglobulins or interleukine-2 preparations), nonsteroid antiinflammatory drugs (diclofenak), inhibitors of tumor necrosis factor (pentoxiphilline), vitamins of group B, infusion therapy, parenteral feeding (on demand), plasmapheresis or biospecific antiproteinase hemosorption.